Neuropeptide Y1 receptor antagonist alleviated osteoarthritis by restoring chondrocyte autophagy through PI3K/AKT/mTOR signaling pathway

This study highlights the NPY Y1 receptor as a promising therapeutic target for OA by demonstrating its role in modulating chondrocyte autophagy via the PI3K/AKT/mTOR pathway. The results support the development of Y1R antagonists as novel OA therapeutics. This work bridges molecular discovery to potential clinical application, offering hope for a transformative approach to OA management.